{
  "docId": "019de071-805e-75da-a9c3-e9573cb6e94f",
  "docSlug": "f179c2894ff7ef65a3c6d24dd4bec442",
  "documentTitle": "Exscientia | IPO Presentation Deck | 60 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7893755,
  "pageNumber": 59,
  "pageCount": 60,
  "prevPage": 58,
  "nextPage": 60,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide highlights three specific bispecific programs as proof points for their platform's efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-805e-75da-a9c3-e9573cb6e94f/59",
  "deckHref": "/decks/019de071-805e-75da-a9c3-e9573cb6e94f",
  "deckJsonHref": "/decks/019de071-805e-75da-a9c3-e9573cb6e94f.json",
  "deckAnchorHref": "/decks/019de071-805e-75da-a9c3-e9573cb6e94f#slide-59",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.13,
        "y": 0.38
      },
      "kind": "list",
      "text": "Dual 5HT1a agonist/5HT2a antagonist; Dual Enzyme inhibitors; Dual DPP-IV/PDE4 Enzyme inhibitor",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a26759c-c8e2-49b8-bd98-64be009e8d70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "We have designed multiple, highly selective bispecific compounds. Our results achieve high potency to independent targets while maintaining high selectivity to avoid related receptors. In contrast to large or linked molecules, we achieve low molecular weight and our molecules are suitable for oral delivery and CNS penetration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea8040f9-c5cb-4893-8855-3189450239c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.038,
        "y": 0.13
      },
      "kind": "title",
      "text": "Effectively impossible using conventional sequential methods",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bc80905-9683-4ca0-98f1-1305900ffa57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.038,
        "y": 0.05
      },
      "kind": "title",
      "text": "New area for small molecules - bispecifics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b169a4c-3dbf-490a-b19d-5ac9339f02ea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 60,
      "from": 4,
      "beatId": "5dda98c6-c560-4b21-aa1c-95b617a27a20",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents a comprehensive solution throughout pages 4-60.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 60,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "3b6b60bf-18b7-4458-bffa-eba1b1ca0583",
      "evidence": "The deck presents a comprehensive loop on the golden circle of problem-solution-benefit.",
      "position": 1,
      "objective": "Explain how Exscientia's AI-driven platform can solve the problem of inefficient drug discovery.",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}